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Abstract
Epstein-Barr virus (EBV), like many other persistent herpes viruses, has acquired numerous mechanisms for
subverting or evading immune surveillance. This study investigates the role of secreted EBV-encoded BARF1
protein (sBARF1) in creating an immune evasive microenvironment. Wild-type consensus BARF1 was expressed
in the human 293 cell line and purified. This native hexameric sBARF1 had inhibitory capacity on macrophage
colony stimulating factor (M-CSF)-stimulated, and not on granulocyte macrophage-colony stimulating factor
(GM-CSF)-stimulated growth and differentiation of myeloid cells. Antibodies specific to hexameric sBARF1 were
able to block this effect. M-CSF was shown to interact with sBARF1 via the protruding N-terminal loops
involving Val38 and Ala84. Each BARF1 hexamer was capable of binding three M-CSF dimers. Mutations in the
BARF1 loops greatly affected M-CSF interaction, and showed loss of growth inhibition. Analysis of the acti-
vation state of the M-CSF receptor c-fms and its downstream kinase pathways showed that sBARF1 prevented
M-CSF-induced downstream phosphorylation. Since M-CSF is an important factor in macrophage differentia-
tion, the effect of sBARF1 on the function of monocyte-derived macrophages was evaluated. sBARF1 affected
overall survival and morphology and significantly reduced expression of macrophage differentiation surface
markers such as CD14, CD11b, CD16, and CD169. Macrophages differentiating in the presence of sBARF1
showed impaired responses to lipopolysaccharide and decreased oxygen radical formation as well as reduced
phagocytosis of apoptotic cells. In conclusion, EBV sBARF1 protein is a potent decoy receptor for M-CSF,
hampering the function and differentiation of macrophages. These results suggest that sBARF1 contributes to the
modulation of immune responses in the microenvironment of EBV-positive carcinomas.
Introduction
Epstein-Barr virus (EBV) is a widespread humangamma-herpesvirus with B lymphocyte and epithelial
cell tropism, which persistently infects about 90% of theworld
population. EBV persistence occurs in a tight balance with the
immune system, and is emphasized by the higher risk for
lymphoproliferative diseases in immunosuppressed patients.
However, EBV is causally linked to several carcinomas and
lymphomas in immunocompetent individuals as well. EBV is
associated with approximately 100% of undifferentiated na-
sopharyngeal carcinomas (NPC) (3,24,42), and about 10% of
gastric carcinomas (GC) worldwide (32,50,58). The EBV ge-
nome contains over 80 open reading frames, of which only a
few latent genes are expressed in EBV-related malignancies
(2,10,27). Strikingly, EBV-positive epithelial malignancies ex-
press a viral oncogene encoded in the BamHI-A rightward
frame 1 (BARF1), which is absent from EBV-positive lym-
phomas (9,16,51). In the lytic cycle, BARF1 is transcribed in
both epithelial and lymphoid cell types (59).
Computer-assisted amino acid sequence analysis of
sBARF1 indicated weak homology with a conserved region
found in several members of the tyrosine kinase family, in-
cluding the receptor for macrophage colony stimulating
factor (M-CSF), platelet-derived growth factor (PDGF) re-
ceptor, fibroblast growth factor (FGF) receptor, and hepato-
cyte growth factor (HGF) receptor (6,52). The homology with
these receptors is restricted to a conserved structural region
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not involved in the ligand binding domains (52). Full-length
BARF1 has homology with the T-cell receptor co-stimulatory
molecule CD80 (54). Prior studies with monomeric Fc-tagged
BARF1 indicated that BARF1 is a viral scavenger of M-CSF,
binding all three isoforms, and acting as a functional an-
tagonist for M-CSF (36,52). However, subsequent studies on
the structure of secreted BARF1 revealed a hexameric mol-
ecule, which may differ in structure and function from mo-
nomeric Fc-tagged BARF1 (18,54,56).
M-CSF is synthesized by many cell types, including en-
dothelial cells, fibroblasts, bone marrow stromal cells, os-
teoblasts, and keratinocytes. Serum levels of M-CSF in
normal adults range from 1.7–8.4 ng/mL (22), but are ele-
vated during pregnancy, infection, lymphomas, and breast,
ovary, and endometrial carcinomas (5,7,22,49). High-level
secreted BARF1 was observed in serum samples of NPC
patients (19). M-CSF is a pleiotropic growth factor with
many roles in the immune system; M-CSF is important for
regulating the viability, proliferation, and differentiation of
mononuclear phagocytes from monocytes to macrophages,
but also for the differentiation of Langerhans and other
dendritic cell (DC) subsets (5,20,28,35,40,48). The most ap-
preciated function of M-CSF relates to the induction of
monocyte differentiation into resident macrophages (M2
macrophages) (14,40).
EBV-infected monocytes have been suggested as a vehicle
for virus transmission between the blood compartment and
oral epithelium, and EBV infection in vitro alters monocyte
function by affecting innate inflammatory functions
(13,30,47,55). Following differentiation into DCs, monocytes
become resistant to apoptosis caused by EBV infection (13).
M-CSF inhibition by secreted BARF1 might be instrumental
for EBV in restricting maturation of macrophage effector
functions, thus ensuring that these immune cells support
dissemination of viral progeny rather than elimination of the
internalized or bound virus. In NPC, lymphocyte infiltration
does not affect prognosis (23,26), but infiltration of NPC with
mononuclear cells is correlated with a higher survival rate
(12,39), indicating their involvement in tumor cell eradica-
tion. An EBV-infected tumor cell, expressing viral antigens
that can be recognized, might thus benefit from local mye-
loid suppression resulting from M-CSF inhibition by BARF1.
Humoral immune responses to BARF1 can be detected, but
are relatively low (18). BARF1 was recently shown to trigger
both CD4 and CD8 cellular immune responses in NPC pa-
tients, providing a basis for specific immunotherapy (29).
However, the lymphocytes from the NPC tumor environ-
ment are functionally impaired (23,26). By binding and
functionally inhibiting M-CSF, sBARF1 might interfere with
myeloid sentinel functions, and thus contribute to an im-
munological silence facilitating immune escape. Clearly,
more insight into how EBV manipulates the immune system
is necessary for the progress of advanced immune therapy.
In this study, an NPC-sequence-derived native hexameric
sBARF1 protein was used to assess its biological effects as a
decoy receptor for M-CSF, and to evaluate its effects on cells
of myeloid lineage. We showed that M-CSF-induced mac-
rophage differentiation, function, and survival is severely
impaired in the presence of native sBARF1, further charac-
terizing it as a viral immune suppressive factor with possible
effects on both viral dissemination and cancer immune es-
cape. Mutations in the N-terminal loops of sBARF1 demon-
strated the specificity of the sBARF1/M-CSF interaction,
indicating that future therapies should be aimed at this site.
Materials and Methods
Cell culture
Human cytokine-dependent MUTZ-3 cells were obtained
from the German collection of microorganisms and cell cul-
tures DSMZ (Braunschweig, Germany), and cultured in
Costar 12-well tissue culture plates (Corning, Amsterdam,
Netherlands), at 0.4 million cells in 2mL MEM-a containing
10% FCS, 100U/mL sodium penicillin, 100 lg/mL strepto-
mycin sulfate, 2mM L-glutamine (P/S/G), and 50lM
b-mercaptoethanol, supplemented with 10% conditioned
medium from the human renal carcinoma cell line 5637
(31,43,44). Peripheral blood mononuclear cells (PBMCs) were
isolated from buffy coats of healthy donors by Ficoll density
gradient centrifugation. CD14+ monocytes were isolated
from PBMCs by magnetic sorting with anti-CD14 microbe-
ads (Miltenyi Biotec, Bergisch Gladbach, Germany), accord-
ing to the manufacturer’s protocol. Monocytes were
differentiated into monocyte-derived macrophages (MoF) in
5–7 days in IMDM medium (Invitrogen, Carlsbad, CA)
supplemented with 10% FCS, P/S/G, and 10 ng/mL human
M-CSF (Miltenyi Biotec). Where indicated, M-CSF was pre-
incubated with purified native human sBARF1 (200 ng/mL
unless indicated otherwise) (18) for 1 h at room temperature
before adding it to the monocytes to create sBARF1-treated
macrophages (sBARF1-treated MoF).
sBARF1 production
Soluble hexameric BARF1 protein (sBARF1), cloned from
a NPC-derived EBV isolate and expressed in HEK293 human
epithelial cells, was purified to homogeneity from serum-free
supernatants by lectin-affinity chromatography as previ-
ously described (18,21).
Site-directed mutagenesis
M-CSF binding site mutants of BARF1 were created using
the Quickchange Lightning multi-site-directed mutagenesis
kit according to the manufacturer’s instructions (Stratagene,
Santa Clara, CA), to incorporate specific mutations into the
original pcDNA4-BARF1 expression vector. Mutant sBARF1
was produced and purified exactly the same as the wild-type
sBARF1.
Immunoprecipitation
Rabbit polyclonal antibodies specifically reactive with native
hexameric BARF1 were covalently bound to Protein-G beads
(GE Healthcare, Waukesha, WI) using 6mg/mL dimethylpi-
milimidate in 0.2M Na2B4O710H2O at pH 9 for 1h at room
temperature, followed by three wash steps with 0.2M ethanol-
amine. sBARF1 and attached protein was immunoprecipitated
(IP) from medium by anti-BARF1 beads, eluted with 0.2M
glycine (pH 3.0), and neutralized with 3M Tris (pH 8.0).
SDS-PAGE and Western blot
Cells were lysed in IP buffer containing Protease Inhibitor
Cocktail (Roche, Basel, Switzerland) and sonicated. Cell debris
was removed by centrifugation and protein concentration
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was determined using the BCA Protein Assay kit (Pierce,
Rockford, IL). Cell extracts and IP samples were diluted in
2· loading buffer (Bio-Rad, Hercules, CA) with b-mercap-
toethanol, denatured for 5min at 95C, and separated on a
12.5% SDS-PAGE gel. After transferring to Hybond ECL ni-
trocellulose membranes (GE Healthcare), the membranes were
blocked in PBS with additional Tween-20 (PBST) containing
3% non-fat dried milk for 1 h at room temperature. Anti-M-
CSF antibodies (1:500; Santa Cruz Biotechnology, Santa Cruz,
CA), or anti-BARF1 4A6 antibodies (1:100) (18), were incu-
bated overnight at 4C in PBST with 5% BSA. After three wash
steps with PBST, the appropriate HRP-labeled secondary an-
tibodies (Dako, Glostrup, Denmark) were incubated 1:2000 in
3% milk for 1h, and the antibody was removed by three wash
steps with PBST, followed by visualization with ECL (GE
Healthcare). Pathscan Multiplex Western Cocktail (#5301) was
used to visualize phosphorylated MAPK, Akt, and phos-
phorylated M-CSF receptor (#3151; Cell Signaling Technology,
Danvers, MA), according to the manufacturer’s protocol.
Viability assay
Approximately 100,000 MoF were cultured in 200 lL
medium per well in 96-well plates. Viability was determined
with a cell proliferation kit (MTT; Roche), according to the
manufacturer’s protocol. Absorbance was measured with a
Tecan Spectafluor at 590 nm.
Giemsa and nitroblue tetrazolium staining
Following methanol fixation, cells were stained with
Giemsa solution (Merck Sharp & Dohme, Whitehouse Sta-
tion, NJ) 1:5 in H2O for 1 h. To determine the production of
free radicals upon lipopolysaccharide (LPS) stimulation,
MoFwere pre-sensitized with 200U/mL human interferon-c
(Miltenyi Biotec) for 2 h. Subsequently 1 lg/mL LPS (E. coli
strain 055:B5; Dako) and 0.04% nitroblue tetrazolium (NBT;
Sigma-Aldrich, Buchs, Switzerland) were added and incu-
bated for 4 h. After treatment, the cells were fixed and light
microphotographs (40 · ) were taken with Leica software
(Wetzlar, Germany).
Flow cytometry
MoFwere harvested with 0.05mM EDTA (Merck Sharp &
Dohme) in PBS and washed with fluorescence-activated cell
sorter (FACS) buffer (0.2% BSA and 0.002% NaN3 in PBS),
before staining with monoclonal antibodies specific for
macrophage surface markers for at least 30min at 4C. The
monoclonal antibodies used were fluorescein isothiocyanate
(FITC)-conjugated IgG1 (isotype control), phycoerythrin
(PE)-conjugated against IgG1 (isotype control), FITC-conju-
gated against CD14, CD16, and CD64, PE-conjugated against
HLA-DR, CD11b, CD11c, CD36, and CD1a (BD Biosciences,
Franklin Lakes, NJ), and FITC-conjugated against CD169
(Abcam, Cambridge, U.K.). After washing, the cells were
analyzed on a FACSCalibur II system (BD Biosciences). The
results were analyzed with CellQuest Pro software.
Phagocytosis assay
MoF were cultured on glass chamber slides during dif-
ferentiation. Jurkat cells were dyed fluorescent green using
PKH67 dye (Invitrogen) according to the manufacturer’s
protocol, 1 day before lethal irradiation with 50 Gy. After 5 h,
apoptotic cells were added to the macrophages. After 1.5 h
incubation, the macrophages were washed four times with
ice-cold PBS and fixed with 4% paraformaldehyde at 4C for
30min. To visualize macrophage contours, the cells were
washed three times with PBS, permeabilized with 0.1% Tri-
ton-X100 in PBS, and incubated with 1:40 rhodamine phal-
loidin (Sigma Aldrich) in PBS and 5% BSA for 1 h at room
temperature. After washing, the slides were cover-slipped,
and pictures were taken using a Leica confocal microscope.
Data analysis
The Wilcoxon signed rank test was performed using
GraphPath-4 statistical software (La Jolla, CA), and p val-
ues < 0.05 were considered significant.
Results
Secreted BARF1 protein binds and functionally
inhibits M-CSF
To evaluate whether the native secreted hexameric form of
BARF1 could bind M-CSF, co-immunoprecipitations were
performed in DMEM supplemented with purified sBARF1 or
M-CSF or both. Protein-G beads covalently linked to anti-
sBARF1 antibody, recognizing the hexameric form of
sBARF1, were used to precipitate BARF1 from medium with
or without M-CSF. Immunoblot analysis revealed that M-
CSF was specifically precipitated when BARF1 was present
in the medium (Fig. 1a), indicating a direct binding of
sBARF1 to M-CSF.
The human myeloid cell line MUTZ-3 was used to eval-
uate whether sBARF1 binding to M-CSF functionally inter-
fered with cell proliferation. These cells are dependent on
human cytokines for in vitro growth, and thus can be used to
evaluate functional cytokine levels. MUTZ-3 cells were cul-
tured in the presence of 10 ng/mL M-CSF, which was pre-
incubated with sBARF1 at different concentrations. As
shown in Fig. 1b, sBARF1 was able to block M-CSF-depen-
dent growth of MUTZ-3 cells in a dose-dependent manner.
Concentrations higher than 17 ng/mL of purified sBARF1
were able to block 10 ng/mL M-CSF, equaling one sBARF1
hexamer binding three M-CSF dimers. In addition, MUTZ-3
cells can also be maintained in the presence of granulocyte
macrophage-colony stimulating factor (GM-CSF), which has
a tertiary structure similar to M-CSF, but a different qua-
ternary structure and receptor interaction. Of note, sBARF1
was not able to block GM-CSF-dependent cell proliferation,
demonstrating its binding specificity for M-CSF, and con-
firming that sBARF1 by itself has no toxic or harmful effect
(Fig. 1b). The proliferation of MUTZ-3 cells in the presence of
sBARF1 could be restored by pre-incubation with a neu-
tralizing antibody against BARF1 (Fig. 1d). These results
showed that sBARF1 is able to functionally inhibit M-CSF,
but not GM-CSF, and that this can be neutralized by specific
antibodies.
Structural basis of the interaction between
M-CSF and sBARF1
Sequence analysis revealed structural homology of
sBARF1 with several growth factor receptors, but gave no
indication which parts of the sBARF1 hexamer are
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responsible for M-CSF binding. M-CSF is a disulfide-linked
dimer with each monomer consisting of a four-alpha-helix
bundle and an anti-parallel beta sheet (38). The M-CSF re-
ceptor binds the M-CSF dimer at its alpha-helix flat face, but
the affinity is weak. Upon binding to the receptor, the M-CSF
dimer undergoes conformational changes, resulting in di-
merization and activation of the receptor (4). Crystallization
results of the sBARF1/M-CSF complex (unpublished data)
indicated that in contrast to the M-CSF receptor, the BARF1
hexamer binds the M-CSF dimer at the beta sheets, with
Val38 and Ala84, located in two protruding N-terminal
loops, as the main interacting residues on sBARF1. To con-
firm these findings, Val38Glu and Ala84Glu single mutants,
a double mutant, and a mutant in which the loop resi-
dues 37–40 were mutated to glycine, were generated. The
double mutant and the loop mutant were secreted as hex-
amers in the culture medium of transfected cells (Fig. 2a).
The intracellular loop mutant resulted in relatively less gly-
cosylated BARF1, possibly relating to folding difficulties
during intracellular trafficking of the translated product.
The single mutants were able to bind M-CSF, but both the
double and the loop mutant were disabled in M-CSF bind-
ing (Fig. 2b), and showed reduced inhibition of M-CSF-
dependent growth of MUTZ-3 cells compared to wild-type
(WT) BARF1 (Fig. 2c).
M-CSF receptor downstream signaling is inhibited
by sBARF1
The effect of sBARF1 in the M-CSF receptor downstream
signaling pathway, involving tyrosine kinases PI3-K and
STAT (14,15,34), was evaluated. Five minutes after exposing
serum-starved MUTZ-3 cells to M-CSF, phosphorylated
(active) M-CSF receptor, Akt, and MAPK were detected (Fig.
3a). Pre-incubating M-CSF with sBARF1 prevented this ac-
tivation of the M-CSF-receptor signaling pathway, whereas
pre-incubation of sBARF1 with a neutralizing antibody re-
stored the signaling through the M-CSF receptor (Fig. 3a).
Since macrophages differentiate in the presence of M-CSF
and express the M-CSF receptor, downstream signaling was
also evaluated in serum-starved MoF. Short-term M-CSF
exposure increased MAPK phosphorylation, whereas pre-
incubation of M-CSF with sBARF1 reduced this MAPK
phosphorylation (Fig. 3b). Thus kinase pathways, activated
FIG. 1. (a) sBARF1 binds and functionally interferes with M-CSF. Immunoprecipitation, using linked anti-sBARF1 beads,
was performed with M-CSF, in the presence or absence of sBARF1. As a control, medium with both sBARF1 and M-CSF was
loaded. M-CSF was specifically precipitated when sBARF1 was present. (b) MUTZ-3 cells were cultured for 3 d, with or
without 10 ng/mL M-CSF or 100U/mL GM-CSF pre-incubated for 1 h with sBARF1, at different concentrations. Growth was
determined using the MTT proliferation test. The growth over 3 d with growth factor was set at 100%, and values at plating
were set at 0%. We found that – 17 ng/mL sBARF1 was sufficient to block the proliferation induced by 10 ng/mL M-CSF, but
not GM-CSF. (c) Inhibitory concentration (IC) values for 10 ng/mL M-CSF and the accompanying standard error of the mean
(SEM). (d) The effect of sBARF1 could partially be restored by pre-incubating sBARF with specific antibodies; 20 ng/mL of
sBARF1 was used to inhibit M-CSF-dependent growth of MUTZ-3 cells. Antibodies against LMP1 were used as a negative
control.
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by M-CSF binding to its receptor, were negatively modu-
lated when M-CSF was scavenged by sBARF1.
Native sBARF1 negatively influences cell morphology
and viability during macrophage differentiation
M-CSF receptor (c-fms) is expressed on both macrophages
and DCs (45,46) and their precursors (11,37). The importance
of M-CSF in DC differentiation is reflected by M-CSF-defi-
cient mice, which have a two- to threefold reduction in
splenic DCs (28). Since M-CSF is essential for macrophage
differentiation (14,40), the effect of sBARF1 on this process
was evaluated using CD14 + monocytes from healthy do-
nors. Differentiated MoF were characterized by enlarged
cytoplasm and irregular plasma membranes with pseudo-
podia. After 5 d of differentiation in the presence of M-CSF,
MoF showed the typical morphology of differentiated mac-
rophages. In contrast, sBARF1-treated MoF remained small
in size with a rounded morphology. Moreover, the addition
of sBARF1 resulted in lower viability in the cultures, as in-
dicated by non-adherent dead cells that were washed away
by the Giemsa staining (Fig. 4a).
To substantiate the observation that sBARF1 negatively
influenced macrophage differentiation and induced cell
death, a viability test was performed, with a read-out based
on mitochondrial activity (i.e., MTT test). In this regard it is
important to note that MoF acquire higher mitochondrial
activity during differentiation (33). The definition of viability
in these assays is both an increase in cell numbers and in the
level of differentiation. When viability of M-CSF-treated
MoF cultured in the absence of sBARF1 measured at day 6
was set at 100%, cells treated with sBARF1 showed a sig-
nificant reduction in viability compared to normal differen-
tiated cells ( p= 0.03; Fig. 4b). This effect was dose-dependent,
and the sBARF1-induced reduction of viability occurred at
20 ng/mL and higher (Fig. 4c), and could be detected as early
as day 3 of differentiation (Fig. 4d). Compared to the un-
treated control group, for which the viability increased upon
differentiation, the viability of the sBARF1-treated cells de-
creased, suggesting cell death (Fig. 4d), which is in accord
with our initial microscope observations (Fig. 4a).
Effects of sBARF1 on macrophage surface
marker expression
To further evaluate the effect of sBARF1 treatment on mac-
rophage differentiation, sBARF1-treated and sBARF1-untreated
MoF were harvested on days 5–7 with EDTA and stained for
key macrophage markers (i.e., CD11b, CD11c, CD14, CD16,
CD36, CD64, CD169, and HLA-DR). Only adherent cells were
FIG. 2. Site-directed mutants of sBARF1 reveal the M-CSF binding site. (a) BARF1 mutants were secreted as hexameric
glycosylated proteins in culture medium. Intracellular loop mutant BARF1 displayed a lower band corresponding to de-
glycosylation, probably due to folding problems, retaining it longer in the Golgi body. (b) Immunoprecipitations with M-CSF,
using linked anti-sBARF1 beads, were performed with WT sBARF1, single mutant Ala84 (Ala84 mut), single mutant Val38
(Val38 mut), double mutant (double mut), and loop mutant sBARF1 (loop mut). M-CSF was not precipitated with the
sBARF1M-CSF double and loop binding site mutants. (c) MUTZ-3 cells were cultured for 3 d in the presence of 10 ng/mL M-
CSF that was pre-incubated for 1 h with a range of sBARF1 concentrations. Growth was determined using the MTT pro-
liferation test (WT, wild-type sBARF1; double mutant, Val38/Ala84 to Glu; loop mutant, loop aa37–40 to Gly).
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harvested, and only viable MoF were selected for flow cyto-
metric analysis. sBARF1-cultured MoF showed a significantly
reduced level of expression of CD14, a pattern recognition co-
receptor for bacterial lipopolysaccharide, and CD11b, a integrin
subunit of macrophage-antigen 1 involved in adherence. Pur-
ified sBARF1 also suppressed the expression of the FccR CD16
and CD169, a macrophage differentiation-specific marker (Fig.
4e), HLA-DR, CD11c, CD64, and CD36, were unaffected (data
not shown). These findings indicate that sBARF1 influences the
differentiation of macrophages.
Impairment of oxygen radical production
by sBARF1-treated macrophages
MoF are responsible for several different effector func-
tions of the immune system against pathogens, which can be
triggered by the TLR4 ligand LPS. Upon activation, MoF
respond by the generation of free oxygen radicals to kill
bacteria that are engulfed by phagocytosis. Oxygen radicals
can be visualized by NBT, which is converted into blue
crystals when oxidized. MoF were incubated with NBT to-
gether with 1lg/mL LPS after being pre-sensitized with
IFN-c. The sBARF1-treated MoF were significantly less ca-
pable of converting NBT than normally-differentiated mac-
rophages ( p= 0.01; Fig. 5a).
sBARF1 specifically affects the phagocytosis
of apoptotic cells
Macrophages are known for their ability to capture and
internalize particles, including pathogens, necrotic cells, ap-
optotic cells, and immune complexes (1). Non-specific
phagocytosis was evaluated with fluorescent microbeads,
and no difference between MoF cultured in the presence or
the absence of sBARF1 was found (data not shown). To
evaluate phagocytosis of apoptotic cells, PKH67-dyed Jurkat
cells were lethally irradiated and added in excess to MoF.
After incubation, the remaining Jurkat cells were washed
away. Macrophages generated from three separate donors
were fixed and stained with rhodamine-phalloidin to visu-
alize actin filaments involved in phagocytosis and analyzed
by confocal microscopy. In the presence of sBARF1, MoF
phagocytosed fewer apoptotic Jurkat cells than control MoF
(Fig. 5b), revealing a functional impairment.
Discussion
EBV, like many other persistent herpes viruses, has ac-
quired numerous mechanisms aimed at subverting or
evading immune surveillance. The secreted hexameric
sBARF1 protein is produced by EBV-related carcinomas (51),
and is expressed during lytic cycle replication of the virus in
both epithelial and lymphoid cell types (59). Since sBARF1
has structural homology with growth factor receptors (52), it
might function by scavenging cytokines as an evasion
mechanism by which EBV-infected cells modulate local im-
mune functions, especially those involving the myeloid lin-
eage, to avoid immune-mediated eradication (6).
Prior investigations showing the inhibitory effects of
BARF1 on myeloid cells were performed with Fc-tagged
BARF1 (36,52). Subsequent studies showed that BARF1 in
human epithelial cells is secreted as a hexameric molecule
(18,54,56). The 3D-folding of the hexameric BARF1 molecule
may be disturbed by the additional Fc-tag. Therefore the use
of a native hexameric protein is preferred. This study showed
that hexameric native sBARF1 could bind M-CSF in a direct
and functionally inhibitory manner. sBARF1 binding pre-
vented M-CSF-stimulated growth of the growth factor-
dependent myeloid cell line MUTZ-3 in a linear fashion, but
had no effect on GM-CSF-induced proliferation, confirming
its specificity for M-CSF. Molecularly, one sBARF1 hexamer
can block the activity of three M-CSF dimers, a result in
agreement with the findings of Tarbouriech et al. (53). These
results led us to investigate which domain at the surface of
sBARF1 was responsible for M-CSF inhibition. Mutational
analysis confirmed the specific interaction of sBARF1 and
M-CSF, as predicted by molecular modeling based on the
M-CSF/sBARF1 co-crystal structure (53). Mutants of the
predicted sBARF1/M-CSF interaction sites showed that
the N-terminal Val38 and Ala84 residues, located in pro-
truding loops, are essential for M-CSF binding. sBARF1
binds M-CSF at the beta sheets, and not at the alpha helices
like the M-CSF receptor (4). Since the M-CSF receptor inter-
action is dependent on conformational changes in the M-CSF
dimer, the mechanism by which sBARF1 prevents M-CSF
receptor activation might be interference with this confor-
mational change.
M-CSF can drive mononuclear phagocyte differentiation
(5,20,28,35,40), but when blocked by sBARF1, this function
was inhibited. Several macrophage-related markers were
negatively influenced by sBARF1, including CD14, CD11b,
CD16, and CD163. In addition, sBARF1-treated MoF were
less capable of producing free oxygen radicals upon
FIG. 3. M-CSF receptor downstream signaling is inhibited
by sBARF1. (a) Serum-starved MUTZ-3 cells were incubated
for 5min with 10 ng/mL M-CSF pre-incubated with or
without 60 ng/mL sBARF1. M-CSF receptor (downstream)
signaling was evaluated using phospho-specific antibodies.
sBARF1 was able to prevent phosphorylation of the M-CSF
receptor and subsequent downstream signaling. Pre-incu-
bation of sBARF1 with specific antibodies was able to oppose
this effect. (b) Monocytes were differentiated for 5 days with
10 ng/mL M-CSF, serum starved for 4 h, and incubated for
5min with 10 ng/mL M-CSF pre-incubated with or without
sBARF1. Antibodies specific to phosphorylated MAPK were
used to evaluate downstream receptor activation.
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stimulation, confirming that sBARF1-treated MoF were
compromised in their anti-inflammatory reaction. Phagocy-
tosis of apoptotic cells was also reduced in MoF treated with
sBARF1. Moreover, downregulation of CD16, a Fc-receptor,
is likely to negatively influence the phagocytosis of antibody-
antigen complexes. All of these features are characteristic for
the suppression of M2 differentiation.
Mononuclear phagocytes are exposed during their differ-
entiation and migration to combinations of growth factors
such as M-CSF, GM-CSF, IL-4, IL-34, IFN-c, and Flt3L, each
of which can contribute to their cellular phenotype (20). M-
CSF is a pleiotropic growth factor with many roles in the
immune system, some of which remain unknown. M-CSF is
an important factor in the regulation of viability, prolifera-
tion, and differentiation of mononuclear phagocytes from
monocytes to macrophages, but it also affects Langerhans
cells and DCs (5,11,20,35,37,40,48). The growth factor GM-
CSF skews monocytes towards M1 macrophages, and
monocytes that continue to be exposed to M-CSF become M2
macrophages (40). M1 macrophages, also called inflamma-
tory macrophages, are considered more inflammatory and
are associated with type 1 cell-mediated immunity; they
produce reactive oxygen species and are considered to have
anti-tumor activity. M2 macrophages, also called resident
macrophages, are important for phagocytosis and are the
first line of antiviral defense. The inhibition of M-CSF by
sBARF1 expressed during lytic replication might allow
monocytes/macrophages to act as a virus transmission ve-
hicle of internalized or bound virus, as opposed to inacti-
vation of the virus (13,55).
Most tumor-associated macrophages (TAMs) are consid-
ered to be of the M2 type, and may even harbor tumor
growth-promoting abilities. The proper differentiation of
professional antigen-presenting DCs, considered to have
FIG. 4. Native sBARF1 negatively influences macrophage morphology and viability during differentiation. Monocytes were
differentiated for 6 d with 10 ng/mL M-CSF with or without 200 ng/mL sBARF1. (a) Differentiated live MoF were wide-
spread adherent cells with a large amount of cytoplasm and pseudopodia (top left). sBARF1-treated MoF were less adherent,
and had a more monocyte-like phenotype with less cytoplasm compared to the untreated cells (top right). Small particles,
which were not seen in the untreated MoF, were dead cells. Differentiated macrophages, fixed and stained with Giemsa
(200 · ), are shown in the lower panels. (b) The MTT proliferation test was used to assess both increased cell numbers and
level of differentiation, for which the term ‘‘viability’’ is used. Cell viability decreases with treatment with sBARF1 (n = 6,
p = 0.03). (c) Monocytes were differentiated for 6 d with a range of concentrations of sBARF1. The effect of sBARF1 can clearly
be seen with a concentration of 20 ng/mL sBARF1. (d) Shown is MTT testing at several time points during the differentiation
of monocytes from one representative donor. The inhibitory effect of 20 ng/mL sBARF1 on the macrophages can be seen from
day 3. The untreated cells showed increased viability, whereas the viability of sBARF1-treated macrophages remained the
same over time. (e) Monocytes from 8 donors were differentiated for 5 d with 10 ng/mL M-CSF with or without 200 ng/mL
sBARF1. Downregulation of surface markers CD14, CD11b, CD16, and CD169 was significant.
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strong potential anti-tumor activity, is also dependent on M-
CSF, which has been shown in recent studies with M-CSF
(receptor)-deficient mice (28).
The results presented here indicate that sBARF1 interferes
with M-CSF, but not with GM-CSF action. BARF1 could thus
selectively impair M2 TAMs in their development and
function. This may appear counter-intuitive in terms of tu-
mor immune escape, but TAMs do not only promote tumor
growth by secreting growth factors and promoting angio-
genesis (41); they can also serve as negative mediators of
tumor growth by mediating anti-tumor cytotoxicity and an-
tigen presentation (25). Since TAM density is positively cor-
related with the prognosis of NPC (12,39), blocking of M-CSF
by sBARF1 might constitute a possible mechanism by which
macrophage-mediated anti-tumor immunity is evaded.
Fc-tagged BARF1 can bind all three M-CSF isoforms, in-
cluding cell surface M-CSF (52). Cell surface M-CSF on tu-
mor cells evokes anti-tumor activity of macrophages in
multiple tumor types, both innately and by linking to the
adaptive arm of the immune system by antigen presentation
to T cells (8,17,57). Since it is unknown whether NPC tumor
cells express M-CSF, we can only speculate that BARF1
might have an effect on this level, interfering with macro-
phage-mediated anti-tumor immunity. Truncation of the
rhBARF1 gene in a lymphocryptovirus rhesus macaque
model resulted in lower efficiency of B-cell immortalization,
possibly related to a loss of M-CSF inhibition (36). Future
in vivo studies should be designed to explore the biological
relevance of WT BARF1 in virus propagation and latency,
and the effects of BARF1 modulation on myeloid cell func-
tion in the tumor area.
It is important to clarify the biological effects operating in
the microenvironment of EBV-associated tumors to under-
stand why these EBV-carrying carcinomas are not properly
eliminated by the immune system. Our data reveal secreted
BARF1 as a viral decoy receptor for M-CSF, functionally
inhibiting M-CSF-dependent growth and activation of the
M-CSF receptor pathway. Secreted BARF1 negatively influ-
ences mononuclear phagocyte differentiation, activation, and
survival, which might contribute to EBV immune evasion.
Therefore, the insights into the functional BARF1M-CSF
binding domains provided by this study could aid in the
development of a small-molecule or antibody-based therapy
to block this myelosuppressive function of sBARF1, thus
allowing more effective immune therapy.
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